Multiple pathway components

The term 'Multiple pathway components' is a non-specific classification used in pharmacological and clinical databases to describe therapeutic agents that exert their effects through the modulation of several distinct biological pathways rather than a single molecular target (IUPHAR/BPS Guide to Pharmacology). This designation is frequently applied to multi-kinase inhibitors, broad-spectrum immunomodulators, or complex biological extracts where the therapeutic efficacy is derived from the synergistic inhibition or activation of multiple proteins across various signaling cascades (ChEMBL Database). Because it encompasses a broad range of biological activities and does not refer to a single, well-defined protein, receptor, or enzyme with a unique UniProt identifier, it lacks the specificity required for standard target-based drug discovery metrics (Nature Reviews Drug Discovery). In the context of biotech analysis, this entry is considered 'incorrect' as it represents a functional grouping or a placeholder for polypharmacological activity rather than a discrete, druggable molecular entity. Drugs associated with this label often demonstrate complex mechanisms of action that involve cross-talk between different cellular signaling networks, making the identification of specific biomarkers for patient selection particularly challenging (PubMed). Consequently, it cannot be associated with a specific molecular weight or crystal structure, serving instead as a category of action for agents with systemic biological effects.

Other names

Multi-targetPolypharmacological targetsNetwork-based targetsSystemic pathway modulation

The mechanism of action involves the simultaneous modulation of multiple distinct signaling nodes or enzymes across various biological pathways to achieve a synergistic therapeutic effect (PubMed).